Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF G469E |
| Therapy | Sorafenib |
| Indication/Tumor Type | nasopharynx carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF G469E | nasopharynx carcinoma | predicted - sensitive | Sorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Nexavar (sorafenib) inhibited growth of a nasopharyngeal carcinoma cell line expressing BRAF G469E in culture (Cancer Res (2024) 84 (7_Supplement): LB412). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract LB412: BRAFp.G469E hotspot mutation promotes nasopharyngeal carcinoma tumorigenesis with potential druggability | Full reference... |